Mammalian hair, roof leaks: Novo's Catalent site in Indiana under FDA scrutiny once again

RegulatoryNegative

AI Analysis

Summary

Novo Nordisk's Indiana manufacturing facility acquired from Catalent faced FDA re-inspection in April, with inspectors identifying mammalian hair contamination in finished drugs and water leaks that compromise product sterility. The facility continues to face regulatory scrutiny for contamination issues.

Outcome Details

FDA re-inspection in April found mammalian hair in finished drugs and water leaks compromising product sterility

Importance:7/10

Sentiment:

-0.90

FDA inspectionmanufacturing contaminationproduct qualityregulatory riskfacility compliance

Related Companies

$NVO $CTLT

Read the original article

Published by Endpoints News on June 4, 2026 4:14 PM

Read Original